Skip to main content

Advertisement

SpringerLink
Log in

Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

The objective of this study was to compare the anatomical and functional outcomes of ranibizumab versus aflibercept for the treatment of macular edema due to central retinal vein occlusion (CRVO) in routine clinical practice.

Methods

Participants in this observational study included 62 treatment-naïve patients with CRVO who received intravitreal injections of either ranibizumab or aflibercept. The demographic data, best-corrected visual acuity (BCVA) and spectral-domain optical coherence tomography (SD-OCT) characteristics were evaluated at baseline and at months 1, 2, 3, 6, 12 and 18 post-treatment.

Results

At month 18, the mean BCVA of ranibizumab-treated eyes increased 7.9 letters, compared to 7.4 letters for eyes receiving aflibercept, with a similar number of injections. There was no statistically significant difference between the two groups in letters or in central subfield thickness at month 18. At the end of the follow-up, 50% of patients in the ranibizumab group and 42.9% in the aflibercept group showed complete resolution of macular edema.

Conclusions

Ranibizumab and aflibercept demonstrated similar anatomical and functional outcomes over 18-month follow-up in patients with macular edema due to CRVO, with a similar number of injections.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Cugati S, Wang JJ, Rochtchina E, Mitchell P (2006) Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. Arch Ophthalmol 124:726–732

    Article  PubMed  Google Scholar 

  2. Klein R, Klein BE, Moss SE, Meuer SM (2000) The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc 98:133–141

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, Kowalski JW, Nguyen H, Wong TY, International Eye Disease Consortium (2010) The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 117:313–319

    Article  PubMed  PubMed Central  Google Scholar 

  4. Rehak J, Rehak M (2008) Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res 33:111–131

    Article  PubMed  PubMed Central  Google Scholar 

  5. Jaulim A, Ahmed B, Khanam T, Chatziralli IP (2013) Branch retinal vein occlusion: epidemiology, pathogenesis, risk factors, clinical features, diagnosis, and complications. An update of the literature. Retina 33:901–910

    Article  PubMed  Google Scholar 

  6. Yau JW, Lee P, Wong TY, Best J, Jenkins A (2008) Retinal vein occlusion: an approach to diagnosis, systemic risk factors and management. Intern Med J 38:904–910

    Article  CAS  PubMed  Google Scholar 

  7. Deobhakta A, Chang LK (2013) Inflammation in retinal vein occlusion. Int J Inflam 2013:438412

    Article  PubMed  PubMed Central  Google Scholar 

  8. Noma H, Funatsu H, Mimura T, Harino S, Hori S (2009) Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Ophthalmology 116:87–93

    Article  PubMed  Google Scholar 

  9. Noma H, Mimura T, Masahara H, Shimada K (2014) Pentraxin 3 and other inflammatory factors in central retinal vein occlusion and macular edema. Retina 34:352–359

    Article  CAS  PubMed  Google Scholar 

  10. Boyd SR, Zachary I, Chakravarthy U, Allen GJ, Wisdom GB, Cree IA, Martin JF, Hykin PG (2002) Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch Ophthalmol 120:1644–1650

    Article  CAS  PubMed  Google Scholar 

  11. Jung SH, Kim KA, Sohn SW, Yang SJ (2014) Association of aqueous humor cytokines with the development of retinal ischemia and recurrent macular edema in retinal vein occlusion. Invest Ophthalmol Vis Sci 55:2290–2296

    Article  CAS  PubMed  Google Scholar 

  12. Chatziralli IP, Jaulim A, Peponis VG, Mitropoulos PG, Moschos MM (2014) Branch retinal vein occlusion: treatment modalities: an update of the literature. Semin Ophthalmol 29:85–107

    Article  PubMed  Google Scholar 

  13. Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, Murahashi WY, Rubio RG (2011) Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 118:2041–2049

    Article  PubMed  Google Scholar 

  14. Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG, Lai P (2012) Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology 119:802–809

    Article  PubMed  Google Scholar 

  15. Campochiaro PA, Sophie R, Pearlman J, Brown DM, Boyer DS, Heier JS, Marcus DM, Feiner L, Patel A, RETAIN Study Group (2014) Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology 121:209–219

    Article  PubMed  Google Scholar 

  16. Heier JS, Clark WL, Boyer DS, Brown DM, Vitti R, Berliner AJ, Kazmi H, Ma Y, Stemper B, Zeitz O, Sandbrink R, Haller JA (2014) Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology 121:1414–1420

    Article  PubMed  Google Scholar 

  17. Korobelnik JF, Holz FG, Roider J, Ogura Y, Simader C, Schmidt-Erfurth U, Lorenz K, Honda M, Vitti R, Berliner AJ, Hiemeyer F, Stemper B, Zeitz O, Sandbrink R, GALILEO Study Group (2014) Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: One-year results of the phase 3 GALILEO study. Ophthalmology 121:202–208

    Article  PubMed  Google Scholar 

  18. Ogura Y, Roider J, Korobelnik JF, Holz FG, Simader C, Schmidt-Erfurth U, Vitti R, Berliner AJ, Hiemeyer F, Stemper B, Zeitz O, Sandbrink R, GALILEO Study Group (2014) Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study. Am J Ophthalmol 158:1032–1038

    Article  CAS  PubMed  Google Scholar 

  19. Farinha C, Marques JP, Almeida E, Baltar A, Santos AR, Melo P, Costa M, Figueira J, Cachulo ML, Pires I, Silva R (2015) Treatment of retinal vein occlusion with ranibizumab in clinical practice: longer-term results and predictive factors of functional outcome. Ophthalmic Res 55:10–18

    Article  PubMed  Google Scholar 

  20. Papakostas TD, Lim L, van Zyl T, Miller JB, Modjtahedi BS, Andreoli CM, Wu D, Young LH, Kim IK, Vavvas DG, Esmaili DD, Husain D, Eliott D, Kim LA (2016) Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab. Eye 30:79–84

    Article  CAS  PubMed  Google Scholar 

  21. Eadie JA, Ip MS, Kulkarni AD (2014) Response to aflibercept as secondary therapy in patients with persistent retinal edema due to central retinal vein occlusion initially treated with bevacizumab or ranibizumab. Retina 34:2439–2443

    Article  CAS  PubMed  Google Scholar 

  22. Pfau M, Fassnacht-Riederle H, Becker MD, Graf N, Michels S (2015) Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion. Ophthalmic Res 54:150–6

    Article  CAS  PubMed  Google Scholar 

  23. Sophie R, Hafiz G, Scott AW, Zimmer-Galler I, Nguyen QD, Ying H, Do DV, Solomon S, Sodhi A, Gehlbach P, Duh E, Baranano D, Campochiaro PA (2013) Long-term outcomes in ranibizumab-treated patients with retinal vein occlusion; the role of progression of retinal nonperfusion. Am J Ophthalmol 156:693–705

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Lehmann-Clarke L, Dirani A, Mantel I, Ambresin A (2015) The effect of switching ranibizumab to aflibercept in refractory cases of macular edema secondary to ischemic central vein occlusion. Klin Monbl Augenheilkd 232:552–5

    Article  CAS  PubMed  Google Scholar 

  25. Lotery AJ, Regnier S (2015) Patterns of ranibizumab and aflibercept treatment of central retinal vein occlusion in routine clinical practice in the USA. Eye (Lond) 29:380–7

    Article  CAS  Google Scholar 

  26. Larsen M, Waldstein SM, Boscia F, Gerding H, Monés J, Tadayoni R, Priglinger S, Wenzel A, Barnes E, Pilz S, Stubbings W, Pearce I, CRYSTAL Study Group (2016) Individualized ranibizumab regimen driven by stabilization criteria for central retinal vein occlusion: twelve-month results of the CRYSTAL study. Ophthalmology 123:1101–1111

    Article  PubMed  Google Scholar 

  27. Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, Brucker AJ, Ferris FL, Hampton GR, Jhaveri C, Melia M, Beck RW, Diabetic Retinopathy Clinical Research Network (2016) Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: Two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology 123:1351–1359

    Article  PubMed  Google Scholar 

  28. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480–1487

    Article  CAS  PubMed  Google Scholar 

  29. Ota M, Tsujikawa A, Murakami T, Kita M, Miyamoto K, Sakamoto A, Yamaike N, Yoshimura N (2007) Association between integrity of foveal photoreceptor layer and visual acuity in branch retinal vein occlusion. Br J Ophthalmol 91:1644–1649

    Article  PubMed  PubMed Central  Google Scholar 

  30. Murakami T, Tsujikawa A, Ohta M, Miyamoto K, Kita M, Watanabe D, Takagi H, Yoshimura N (2007) Photoreceptor status after resolved macular edema in branch retinal vein occlusion treated with tissue plasminogen activator. Am J Ophthalmol 143:171–173

    Article  CAS  PubMed  Google Scholar 

  31. Rotsos TG, Moschos MM (2008) Cystoid macular edema. Clin Ophthalmol 2:919–930

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 2nd Department of Ophthalmology, Attikon Hospital, University of Athens, 28, Papanastasiou street, Agios Dimitrios, 17342, Athens, Greece

    Irini Chatziralli & Panagiotis Theodossiadis

  2. 2nd Department of Ophthalmology, Henry Dunant Hospital, Athens, Greece

    George Theodossiadis

  3. 1st Department of Ophthalmology, University of Athens, Athens, Greece

    Marilita M. Moschos

  4. 2nd Department of Ophthalmology, Ophthalmiatrion Athinon, Athens, Greece

    Panagiotis Mitropoulos

Authors
  1. Irini Chatziralli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. George Theodossiadis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marilita M. Moschos
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Panagiotis Mitropoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Panagiotis Theodossiadis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Irini Chatziralli.

Ethics declarations

Funding

No funding was received for this research.

Conflict of interest

All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria, educational grants, or other equity interest) or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.

Ethical approval

The study adhered to the Declaration of Helsinki and was approved by the institutional review board as a retrospective study. Written informed consent was obtained from all participants.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chatziralli, I., Theodossiadis, G., Moschos, M.M. et al. Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data. Graefes Arch Clin Exp Ophthalmol 255, 1093–1100 (2017). https://doi.org/10.1007/s00417-017-3613-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-017-3613-1

Keywords

Search

Navigation